AAAAI Annual Meeting - American Academy of Allergy, Asthma, and Immunology Annual Meeting

Patients with hereditary angioedema who received sebetralstat earlier had faster complete resolution of their attacks.

Detailed findings will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

The data comes from 2 phase 4 trials, ENABLE and EMPOWER, which evaluated lanadelumab and the outcomes of treatment in adolescents with hereditary angioedema.